A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles

NCT02543970 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2015-09-09

No results posted yet for this study

Summary

The primary objective of this study is to confirm the safe and effective use of the Celluma3 for the reduction in the appearance of periorbital wrinkles.

Conditions

  • Wrinkled Structure

Sponsors & Collaborators

  • BioPhotas

    lead INDUSTRY

Principal Investigators

  • Jesse Mitchell, MD, FAAD

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02543970 on ClinicalTrials.gov